SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Sodium chloride (0.9%) provides isotonic concentration of sodium and chloride ions to maintain extracellular fluid volume and osmolarity. Potassium chloride (0.22%) provides potassium ions essential for nerve conduction, muscle contraction, and acid-base balance.
| Metabolism | Electrolytes (sodium, potassium, chloride) are not metabolized; they are excreted primarily by the kidneys. |
| Excretion | Renal: Sodium >95% (glomerular filtration and variable tubular reabsorption); Potassium >90% (glomerular filtration and tubular secretion/reabsorption). Fecal <5%. |
| Half-life | Not applicable (endogenous substances); distribution half-life ~1–2 hours for infused dose; clinical context: no true elimination half-life due to homeostatic regulation; steady-state achieved with continuous infusion. |
| Protein binding | Sodium: negligible; Potassium: negligible. |
| Volume of Distribution | Sodium: 0.35–0.45 L/kg (extracellular fluid); Potassium: 0.4–0.5 L/kg (total body water with predominant intracellular distribution, but initial distribution volume reflects extracellular space). |
| Bioavailability | IV: 100% (sodium and potassium); no oral form for this combination; enteral or topical bioavailability not applicable for IV route. |
| Onset of Action | 0.9% NaCl: immediate upon IV infusion; 0.22% KCl: onset of potassium effect within 15–30 minutes after IV infusion. |
| Duration of Action | While infusion continues; effects persist for minutes to hours after cessation depending on compartment re-equilibration; continuous infusion required to maintain electrolyte balance. |
| Molecular Weight | 58.44 (NaCl); 74.55 (KCl) |
Intravenous infusion; typical adult dose is 1-2 L over 24 hours, titrated to fluid and electrolyte needs. Maximum rate 1 L/hour under controlled conditions.
| Dosage form | INJECTABLE |
| Renal impairment | GFR <10 mL/min: reduce volume to 500-1000 mL/24h and monitor potassium closely. GFR 10-50 mL/min: standard dosing with monitoring. |
| Liver impairment | No dose adjustment required; monitor potassium in severe hepatic impairment (Child-Pugh C) due to risk of hyperkalemia. |
| Pediatric use | Weight-based: 0.9% sodium chloride/0.22% potassium chloride at 2-10 mL/kg/hour; adjust based on serum electrolytes and fluid balance. |
| Geriatric use | Use lower initial infusion rates (e.g., 0.5-1 L over 24 hours) and monitor for fluid overload and hyperkalemia due to decreased renal function. |
| 1st trimester | Safe; essential for maintenance of fluid and electrolyte balance. No known teratogenic risk. Use as clinically indicated. |
| 2nd trimester | Safe; used for rehydration and electrolyte replacement. No fetal harm reported. |
| 3rd trimester | Safe; avoid excessive administration that may lead to fluid overload or hyperkalemia in the mother, which could affect the fetus. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Sodium and potassium ions cross the placenta freely; concentrations equilibrate between maternal and fetal circulations. No evidence of adverse fetal effects at therapeutic doses. |
| Breastfeeding | Excreted into breast milk at low concentrations; considered compatible with breastfeeding. Monitor infant for signs of electrolyte imbalance if high doses are given to the mother. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | No evidence of teratogenicity in any trimester when used appropriately. Both sodium chloride and potassium chloride are essential electrolytes; adverse fetal effects are only anticipated with severe maternal electrolyte disturbances. |
| Fetal Monitoring | Monitor serum electrolytes, renal function, and fluid balance periodically. In pregnancy, assess for signs of fluid overload or electrolyte imbalance; fetal heart rate monitoring may be indicated if maternal condition requires intensive therapy. |
| Fertility Effects | No known effects on fertility. This solution does not interfere with reproductive function. |
■ FDA Black Box Warning
No FDA black box warning.
| Common Effects | fluid replacement |
| Serious Effects |
HyperkalemiaHypernatremiaSevere renal impairment with oliguria or anuriaFluid overload states (e.g., congestive heart failure, edema) where sodium or potassium restriction is required
| Precautions | Use with caution in patients with heart failure, renal impairment, or conditions predisposing to fluid overload., Monitor serum electrolytes, renal function, and acid-base balance regularly., Rapid administration of potassium can cause fatal hyperkalemia; avoid bolus injection., Use with caution in patients with hyperkalemia, acute dehydration, or concurrent use of potassium-sparing diuretics. |
| Food/Dietary | No specific food interactions. Patients should maintain normal dietary intake as tolerated unless otherwise directed by their healthcare provider. |
| Clinical Pearls | Use for maintenance fluid therapy in patients with hypokalemia or at risk for potassium depletion. Monitor serum potassium levels closely, especially in renal impairment. Avoid in hyperkalemia or severe renal failure. Rate of infusion should be adjusted based on clinical status, serum electrolytes, and fluid balance. |
| Patient Advice | Do not use this solution if it is cloudy, discolored, or contains particles. · Inform your healthcare provider if you have kidney problems or are on a potassium-restricted diet. · Report any signs of fluid overload (shortness of breath, swelling) or hyperkalemia (muscle weakness, irregular heartbeat). · This solution is for intravenous use only and will be administered by a healthcare professional. |
Loading safety data…